ET
BPMC

Entropy Technologies’s Blueprint Medicines BPMC Stock Holding History

Entropy Technologies’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,722
Closed -$1.12M – 829
2025
Q2 		$1.12M Buy
+8,722
New +$906K 0.09% 281
2024
Q4 		– Sell
-10,800
Closed -$999K – 743
2024
Q3 		$999K Buy
+10,800
New +$1.07M 0.1% 264
2024
Q2 		– Sell
-3,866
Closed -$367K – 688
2024
Q1 		$367K Sell
3,866
-431
-10% -$37K 0.04% 518
2023
Q4 		$396K Buy
+4,297
New +$278K 0.07% 389

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Entropy Technologies's BPMC Position: Q3 2025 in Review

Entropy Technologies sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 8,722 shares — an estimated $1.12M sold.

Entropy Technologies first reported a position in BPMC in Q4 2023 and held it in 4 quarters. The position peaked at $1.12M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Entropy Technologies reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Entropy Technologies sold 8,722 Blueprint Medicines shares in Q3 2025, an estimated $1.12M.
  • Entropy Technologies first reported a position in Blueprint Medicines in Q4 2023 and held it in 4 quarters.
  • Entropy Technologies's Blueprint Medicines position peaked at $1.12M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Entropy Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.